Skip to main content

Table 1 Changes of ER-β scores between treatment groups

From: Estrogen receptor alpha/beta ratio and estrogen receptor beta as predictors of endocrine therapy responsiveness–a randomized neoadjuvant trial comparison between anastrozole and tamoxifen for the treatment of postmenopausal breast cancer

 

A

P

T

Total

Pre-treatment

   

Mean ± SD

3.21 ± 2.81

3.21 ± 2.63

4.17 ± 2.57

3.51 ± 2.67

Median (minimum–maximum)

3 (0–8)

4 (0–7)

5 (0–8)

4 (0–8)

Total (n)

24

28

23

75

Post-treatment

   

Mean ± SD

4 ± 2.31

2.93 ± 2.45

5 ± 2.04

3.91 ± 2.41

Median (minimum–maximum)

4 (0–7)

4 (0–7)

6 (0–8)

4 (0–8)

Total (n)

25

28

23

76

  1. A: anastrozole group; P: placebo group; T: tamoxifen group; SD: standard deviation.
  2. ANOVA with repeated measures using rank transformation: treatment (p = 0.3312) and group × treatment (p = 0.3052).